Prevention of Diabetes-Associated Cognitive Dysfunction Through Oral Administration of Lipopolysaccharide Derived From


Journal

Frontiers in immunology
ISSN: 1664-3224
Titre abrégé: Front Immunol
Pays: Switzerland
ID NLM: 101560960

Informations de publication

Date de publication:
2021
Historique:
received: 06 01 2021
accepted: 13 08 2021
entrez: 13 9 2021
pubmed: 14 9 2021
medline: 29 9 2021
Statut: epublish

Résumé

Diabetes-related cognitive dysfunction (DRCD) is a serious complication induced by diabetes. However, there are currently no specific remedies for DRCD. Here, we show that streptozotocin-induced DRCD can be prevented without causing side effects through oral administration of lipopolysaccharide (LPS) derived from

Identifiants

pubmed: 34512619
doi: 10.3389/fimmu.2021.650176
pmc: PMC8429836
doi:

Substances chimiques

Csf1r protein, mouse 0
Lipopolysaccharides 0
Neuroprotective Agents 0
Receptors, Granulocyte-Macrophage Colony-Stimulating Factor 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

650176

Informations de copyright

Copyright © 2021 Mizobuchi, Yamamoto, Yamashita, Nakata, Inagawa, Kohchi and Soma.

Déclaration de conflit d'intérêts

HM, KY, MY, HI, and G-IS are employed by the Control of Innate Immunity, Collaborative Innovation Partnership. YN, HI, CK, and G-IS are employed by Macrophi Inc. This does not affect our adherence to journal policies on sharing data and materials.

Références

Nat Rev Immunol. 2010 Mar;10(3):170-81
pubmed: 20154735
Anticancer Res. 2009 Mar;29(3):859-64
pubmed: 19414320
Mol Cell. 2020 Jul 2;79(1):43-53.e4
pubmed: 32464093
J Immunol. 2010 Jun 15;184(12):7207-18
pubmed: 20483760
J Immunol. 2005 Nov 1;175(9):5885-94
pubmed: 16237081
J Neural Transm Suppl. 2007;(72):217-33
pubmed: 17982898
Nat Neurosci. 2016 Jan;19(1):94-101
pubmed: 26642091
Brain Behav Immun. 2016 Jul;55:260-272
pubmed: 27132056
Acta Neuropathol Commun. 2020 May 19;8(1):72
pubmed: 32430064
Glia. 2008 Jan 1;56(1):69-77
pubmed: 17932942
J Exp Med. 2013 Jan 14;210(1):157-72
pubmed: 23296467
Front Cell Neurosci. 2018 Jul 03;12:178
pubmed: 30018535
Neurobiol Dis. 2020 Aug;142:104956
pubmed: 32479996
Anticancer Res. 2016 Jul;36(7):3599-605
pubmed: 27354629
Anticancer Res. 2015 Aug;35(8):4467-72
pubmed: 26168488
Nutr Res Pract. 2011 Oct;5(5):435-42
pubmed: 22125681
J Neuroimmune Pharmacol. 2017 Jun;12(2):292-304
pubmed: 27734267
Nat Rev Endocrinol. 2018 Oct;14(10):591-604
pubmed: 30022099
Neuron. 2014 Apr 16;82(2):380-97
pubmed: 24742461
Mol Ther. 2020 Jan 8;28(1):129-141
pubmed: 31677955
Nature. 2018 Apr;556(7701):332-338
pubmed: 29643512
Brain. 2009 Apr;132(Pt 4):1078-92
pubmed: 19151372
Oncotarget. 2016 Jan 12;7(2):1354-66
pubmed: 26595525
Anticancer Res. 2007 Nov-Dec;27(6A):3701-6
pubmed: 17970031
J Neurosci. 2014 Apr 23;34(17):5882-94
pubmed: 24760848
Food Sci Nutr. 2014 Nov;2(6):638-46
pubmed: 25493180
J Neuroinflammation. 2017 Dec 04;14(1):236
pubmed: 29202771
Cell Physiol Biochem. 2009;24(3-4):141-52
pubmed: 19710528
Anticancer Res. 2011 Jul;31(7):2467-76
pubmed: 21873161
Cancer Biol Ther. 2014 Jan;15(1):99-107
pubmed: 24100343
Biotechniques. 2003 Feb;34(2):374-8
pubmed: 12613259
Nat Commun. 2019 Aug 21;10(1):3758
pubmed: 31434879
Neural Regen Res. 2021 Oct;16(10):1928-1934
pubmed: 33642362
PLoS One. 2018 Jun 1;13(6):e0198493
pubmed: 29856882
J Neuroinflammation. 2014 Jul 28;11:132
pubmed: 25065370
J Exp Med. 2019 Nov 4;216(11):2546-2561
pubmed: 31601677
In Vivo. 2016 May-Jun;30(3):205-11
pubmed: 27107076
J Appl Microbiol. 2002;92(2):247-55
pubmed: 11849352
J Appl Toxicol. 2020 Oct;40(10):1342-1352
pubmed: 32346895
FASEB J. 2015 Jun;29(6):2545-54
pubmed: 25757564
Sci Rep. 2019 Apr 8;9(1):5790
pubmed: 30962497
Neural Regen Res. 2015 Jul;10(7):1050-2
pubmed: 26330820
Methods Enzymol. 2006;411:134-93
pubmed: 16939790
Blood. 2012 Oct 11;120(15):3152-62
pubmed: 22919031
J Neurosci. 2005 Apr 27;25(17):4442-51
pubmed: 15858070
PLoS One. 2020 Apr 2;15(4):e0230427
pubmed: 32240179
J Biol Chem. 2001 May 25;276(21):18519-28
pubmed: 11279072
J Cell Sci. 2011 Jun 15;124(Pt 12):2021-31
pubmed: 21610095
J Cancer Res Clin Oncol. 2001 Dec;127(12):727-32
pubmed: 11768612
Food Sci Nutr. 2017 Nov 20;6(1):197-206
pubmed: 29387379
J Neurosci Methods. 2010 Mar 30;187(2):243-53
pubmed: 20097228
Neuroinformatics. 2016 Oct;14(4):479-81
pubmed: 27166960
FASEB J. 2002 Apr;16(6):601-3
pubmed: 11919167
Eur J Immunol. 2009 Jul;39(7):1902-13
pubmed: 19585511
Int Immunopharmacol. 2008 Oct;8(10):1354-76
pubmed: 18687298
N Engl J Med. 2002 Sep 19;347(12):869-77
pubmed: 12239255
Nat Genet. 2002 Dec;32 Suppl:496-501
pubmed: 12454644
Cell. 2014 Jul 17;158(2):300-313
pubmed: 25036630
PLoS One. 2018 Mar 27;13(3):e0195008
pubmed: 29584779
Nat Rev Immunol. 2013 Mar;13(3):206-18
pubmed: 23435332
J Neuropathol Exp Neurol. 2018 Mar 1;77(3):199-206
pubmed: 29319809
Anticancer Res. 2011 Jul;31(7):2431-6
pubmed: 21873155
Sci Transl Med. 2020 Jan 15;12(526):
pubmed: 31941827
Brain. 2008 Jun;131(Pt 6):1416-32
pubmed: 18234698
Anticancer Res. 2016 Jul;36(7):3693-8
pubmed: 27354642
Toxicology. 2004 May 3;197(3):213-28
pubmed: 15033544
Immunology. 1999 Jun;97(2):226-31
pubmed: 10447736

Auteurs

Haruka Mizobuchi (H)

Control of Innate Immunity, Collaborative Innovation Partnership, Kagawa, Japan.

Kazushi Yamamoto (K)

Control of Innate Immunity, Collaborative Innovation Partnership, Kagawa, Japan.

Masashi Yamashita (M)

Control of Innate Immunity, Collaborative Innovation Partnership, Kagawa, Japan.

Yoko Nakata (Y)

Research and Development Department Macrophi Inc., Kagawa, Japan.

Hiroyuki Inagawa (H)

Control of Innate Immunity, Collaborative Innovation Partnership, Kagawa, Japan.
Research and Development Department Macrophi Inc., Kagawa, Japan.
Research Institute for Healthy Living, Niigata University of Pharmacy and Applied Life Sciences, Niigata, Japan.

Chie Kohchi (C)

Control of Innate Immunity, Collaborative Innovation Partnership, Kagawa, Japan.
Research and Development Department Macrophi Inc., Kagawa, Japan.

Gen-Ichiro Soma (GI)

Control of Innate Immunity, Collaborative Innovation Partnership, Kagawa, Japan.
Research and Development Department Macrophi Inc., Kagawa, Japan.
Research Institute for Healthy Living, Niigata University of Pharmacy and Applied Life Sciences, Niigata, Japan.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH